Key Highlights
- Sun Pharmaceutical Industries has presented a binding $12 billion all-cash proposal to purchase Organon (OGN)
- Shares of OGN climbed 41% to reach $8.25 on Friday, following Thursday’s 18% increase to $6.91
- The Indian drugmaker has concluded more than three months of extensive due diligence and is securing financing through JPMorgan and MUFG
- Should the transaction close, it would mark the biggest international M&A deal ever executed by an Indian pharmaceutical firm
- Shares of Sun Pharmaceutical declined 3% on Mumbai exchanges after news broke
A dramatic two-day rally has transformed Organon’s trading performance. The women’s healthcare specialist based in New Jersey saw its shares explode 41% higher on Friday morning, reaching $8.25, building on the previous day’s 18% surge after news surfaced that Sun Pharmaceutical Industries had delivered a formal $12 billion acquisition proposal.
According to a report published by India’s Economic Times, the pharmaceutical giant headquartered in Mumbai has progressed past the preliminary investigation phase and delivered a binding, all-cash takeover proposal. Sun Pharma’s pursuit of this acquisition has spanned more than a three-month period.
With Organon’s present market capitalization hovering around $1.8 billion, the $12 billion proposal represents a significant premium above the company’s existing market value.
The transaction’s financial backing involves several prominent global institutions. JPMorgan alongside Japan’s MUFG are among the international banking partners assisting Sun Pharma with funding arrangements for the acquisition.
Organon’s Corporate History
Organon emerged as an independent entity through a spinoff from Merck in 2021. The company specializes in women’s reproductive health, birth control, and fertility treatments, while maintaining additional product lines in dermatology, neurological conditions, and heart health.
The organization has navigated through challenging times recently. In October 2025, Chief Executive Officer Kevin Ali resigned following an internal board probe that uncovered what the company characterized as questionable sales tactics employed to artificially boost quarterly performance figures.
This marks the second time Sun Pharma’s pursuit of Organon has become public knowledge. Earlier in January, the Economic Times disclosed that Sun Pharma had submitted a preliminary, non-binding cash offer and was gearing up to commence due diligence procedures. Friday’s development signals meaningful advancement beyond that initial phase.
Implications for Sun Pharma
If finalized, this transaction would establish a new benchmark as the most substantial international acquisition in the history of Indian pharmaceutical companies — a milestone achievement for the industry.
Sun Pharmaceutical’s stock price moved lower following the announcement, falling 3% on Mumbai trading floors Friday. Such negative market reactions typically occur when acquiring entities reveal major transactions requiring substantial debt financing.
Both Organon and Sun Pharmaceutical declined to provide statements to media outlets when contacted for comment during the reporting period.
Prior to this week’s explosive movement, OGN had been languishing at significantly depressed price levels. The consecutive daily advances of 18% and 41% signal a remarkable reversal in investor confidence surrounding the equity.
As of Friday morning trading, Sun Pharma is reportedly in the concluding phases of the acquisition bid, with financial backing being finalized in conjunction with the binding proposal submission.
